Biogen Inc patent expiration
1. Tecfidera patent expiration
TECFIDERA's oppositions filed in EPO
TECFIDERA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803840 | BIOGEN INC | Utilization of dialkylfumarates |
Apr, 2018
(6 years ago) | |
| US8524773 | BIOGEN INC | Utilization of dialkylfumarates |
Apr, 2018
(6 years ago) | |
| US7619001 | BIOGEN INC | Utilization of dialkylfumarates |
Apr, 2018
(6 years ago) | |
| US8759393 | BIOGEN INC | Utilization of dialkylfumarates |
Jul, 2018
(6 years ago) | |
| US6509376 | BIOGEN INC | Utilization of dialkyfumarates |
Oct, 2019
(4 years ago) | |
| US7320999 | BIOGEN INC | Dimethyl fumarate for the treatment of multiple sclerosis |
May, 2020
(4 years ago) | |
| US8399514 | BIOGEN INC | Treatment for multiple sclerosis |
Feb, 2028
(3 years from now) | |
| US10391160 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(10 years from now) | |
| US10994003 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(10 years from now) | |
| US10555993 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(10 years from now) | |
| US11246850 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| US11007166 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| US11007167 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| US10959972 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| US11129806 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2018 |
| M(M-260) | Feb 05, 2023 |
Drugs and Companies using DIMETHYL FUMARATE ingredient
NCE-1 date: 27 March, 2017
Market Authorisation Date: 27 March, 2013
Treatment: Method of treating an autoimmune disease selected from autoimmune polyarthritis and multiple sclerosis but not treating psoriatic arthritis; Method of treating multiple sclerosis; Method of treating r...
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of TECFIDERA before it's drug patent expiration?
More Information on Dosage
TECFIDERA family patents
2. Vumerity patent expiration
VUMERITY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10080733 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(9 years from now) | |
| US8669281 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9090558 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(9 years from now) | |
Drugs and Companies using DIROXIMEL FUMARATE ingredient
Market Authorisation Date: 29 October, 2019
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of VUMERITY before it's drug patent expiration?
More Information on Dosage
VUMERITY family patents
3. Zurzuvae patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512165 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(9 years from now) | |
| US11236121 | BIOGEN INC | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid |
Aug, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10342810 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(9 years from now) | |
| US10172871 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(9 years from now) | |
| US11884696 | BIOGEN INC | Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid |
Dec, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2028 |
Drugs and Companies using ZURANOLONE ingredient
NCE-1 date: 01 November, 2027
Market Authorisation Date: 31 October, 2023
Treatment: Method of treating postpartum depression
Dosage: CAPSULE
More Information on Dosage
ZURZUVAE family patents